Scarica l'app Stockscreener
9.90
48.30%
-9.25
Dopo l'orario di chiusura:
9.87
-0.03
-0.30%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ERAS Giù?
Forum
Previsione
Erasca Inc Borsa (ERAS) Ultime notizie
Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial - Yahoo Finance
Erasca: Strong Data Overshadowed By A Patient Death And A Patent Fight (NASDAQ:ERAS) - Seeking Alpha
Erasca Stock Sinks 48% in Race for Pancreatic Cancer Miracle Drug. What’s Behind the Sell-Off. - Barron's
Erasca (NASDAQ: ERAS) details 2026 virtual meeting and executive pay - Stock Titan
These Stocks Are Today’s Movers: Oracle, AMD, Intel, Corning, Centene, Erasca, Rambus, Coca-Cola, UPS, and More - Barron's
Erasca, Inc. (ERAS) Discusses Preliminary Phase I Data and Differentiation of Pan-RAS Molecular Glue ERAS-0015Slideshow (NASDAQ:ERAS) 2026-04-28 - Seeking Alpha
Erasca (ERAS) Stock Plummets 50% Following Trial Death and Patent Dispute - parameter.io
Erasca (ERAS) Shares Plunge 50% Following Trial Fatality and Patent Dispute - Blockonomi
Erasca shares cut in half after patient death in clinical trial - Investing.com
Cancer Drug Developer Erasca Sinks by Record 55% After Patient Death - Bloomberg
Erasca, Inc. Shareholders Are Encouraged to Reach Out to - GlobeNewswire
Erasca, Inc. Investigated For Securities Fraud; Block & - GlobeNewswire
ERAS Stock Slides As Legal And Clinical Risks Rattle Traders - StocksToTrade
Boehringer’s obesity drug shows 16.6% weight loss; more data needed - statnews.com
Why Is Cancer Drug Developer Erasca Stock Plunging On Tuesday? - Benzinga
High-flying Revolution Medicines threatens to sue a cancer drug competitor with licensed Chinese drug - The Business Journals
H.C. Wainwright reiterates Erasca stock rating on phase 1 data By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Erasca stock rating on phase 1 data - Investing.com
S&P 500 Futures Fall in Premarket Trading; Erasca, Extra Space Storage Lag - Barron's
Revolution Medicines rival Erasca falls after early-stage trial data for cancer therapy - Seeking Alpha
Revolution levels legal threat on Erasca as pancreatic cancer rivalry heats up - BioSpace
Erasca shares sink after patient death in early-stage cancer drug trial - marketscreener.com
BofA raises Erasca stock price target to $9 on trial data - Investing.com
FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results - Yahoo Finance
Biopharmaceutical company Erasca, Inc. (ERAS) shares plunged 36.6% in pre-market trading after the company released early clinical trial data for its experimental cancer therapy. - Bitget
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
Erasca touts strong, though preliminary, results in trial of pancreatic and lung cancer therapy - statnews.com
Erasca Shares Phase 1 ERAS-0015 Data: 62% NSCLC Response, ctDNA Clearance Signals - Yahoo Finance
Erasca think it can best RevMed in RAS war, but patient death gives investors pause - FirstWord Pharma
Erasca shares plummet after hours due to patient death in early-stage cancer trial - Bitget
Erasca Reports Encouraging Phase 1 Data for ERAS-0015 - TipRanks
Erasca reports positive early trial data for pan-RAS drug - Investing.com
Early ERAS-0015 RAS-mutant cancer data from Erasca (NASDAQ: ERAS) - Stock Titan
Erasca stock tumbles 5% on cancer drug trial data - Investing.com
Erasca stock tumbles 5% on cancer drug trial data By Investing.com - Investing.com India
Erasca reports positive early trial data for pan-RAS drug By Investing.com - Investing.com Canada
Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors - The Manila Times
ERAS Stock Slides As Revolution Study Rattles Traders - StocksToTrade
According to the latest publicly available documents from the U.S. Securities and Exchange Commission (SEC), biopharmaceutical company Revolution Medicines has officially demanded that Erasca immediately cease all research, development, and commer - Bitget
Erasca Inc revolution medicines alleges Erasca's Eras-0015 infringes U.S. patent no. 12,409,225 - marketscreener.com
Erasca Highlights ERAS-0015 Phase 1 Data Update - TipRanks
Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 - The Manila Times
Cancer drug developer Erasca sets 4:30 p.m. call on ERAS-0015 data - Stock Titan
Stifel raises Erasca stock price target to $30 on RAS program - Investing.com
Does Erasca (ERAS) Tighten ERAS-0015 Timeline To Signal Confidence Or Manage Clinical Expectations? - simplywall.st
Erasca stock surges 42% in a week: Here's what you should know - MSN
ERAS stock slumps against RVMD rally — analyst stays bullish - MSN
Erasca's Impressive Run: From $2 To $24 In Less Than 6 Months - RTTNews
Erasca stock reaches 52-week high at 23.65 USD By Investing.com - Investing.com India
ERAS Stock Price, Quote & Chart | ERASCA INC (NASDAQ:ERAS) - ChartMill
Erasca stock reaches 52-week high at 23.65 USD - Investing.com
Sanofi research priorities in flux as new CEO logs in - statnews.com
ERAS (Erasca Inc.) shares climb 4.28% after posting narrower than expected Q4 2025 loss.Top Trending Breakouts - Cổng thông tin điện tử tỉnh Lào Cai
Can Erasca be biotech’s next big thing? We’ll see - statnews.com
ERAS (Erasca Inc.) reports narrower than expected Q4 2025 loss, shares gain over four percent on positive investor sentiment.Shared Trade Ideas - UBND thành phố Hải Phòng
Erasca (ERAS) Quarter End | Erasca Inc. Reports Narrower Loss, 8.3% EPS BeatDividend Suspension - Xã Thanh Hà
Erasca Stock On Fire: Up 37% With 6-Day Winning Streak - Trefis
Erasca Stock Rockets 37% With 6-Day Winning Streak - Trefis
0.29%
0.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):